Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep ...

Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's ...

Arizona has its fair share of place names that outsiders, and sometimes even locals, struggle to pronounce. If you’ve ever pronounced Prescott as “Press-scott” instead of “Press-kitt” or called the ...

Biotech company Moderna said Thursday it plans to cut 10% of its global workforce and expects to have fewer than 5,000 employees by the end of the year. The move is part of the company's ongoing ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, announced Thursday that it will lay off about 10% of its workforce. Moderna CEO ...

Moderna, based in Cambridge, will lay off 10% of its workforce and expects “to be fewer than 5,000 colleagues strong” by the end of the year as part of its effort to cut costs. In a statement on ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks to several potential product launches. But before you give up on this ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ...

Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:MRNA) in its ongoing patent battle with ...

The Department of Health and Human Services (HHS) is canceling hundreds of millions of dollars in funding pledged to Moderna to help the company develop, test and license mRNA-based vaccines to combat ...